Teva appoints two to executive team

Friday, August 3, 2012 11:07 AM

Teva Pharmaceutical, a global pharmaceutical company based in Israel, has appointed Dr. Carlo De Notaristefani as president and CEO of global operations and Aharon (Arik) Yaari as executive vice president of newly created community and institutional affairs.

De Notaristefani has over 25 years of international experience with extensive technical, operational, manufacturing and P&L experience. Most recently, De Notaristefani was at Bristol-Myers Squibb (BMS) where he served as president of technical operations and global support functions. Before joining BMS, he held several senior positions in manufacturing and supply chain at Aventis Pharmaceuticals. Earlier in his career, De Notaristefani held positions at Hoechst Marion Roussel, Marion Merrell Dow and Dow Chemical.

Yaari joined Teva in 1981 and has served as group vice president of global API, and most recently as group vice president of Teva generics systems. In his new position, Yaari will execute on Teva’s global commitment to social responsibility, philanthropy, institutional affairs and academic relations.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs